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Abstract
Background: Smoking remains a leading health risk factor among Europeans. Tobacco, together with other factors,
will lead to an expansive epidemic of chronic diseases, including COPD, among the working population in Russia.
The general aim of the RESearch on the PrEvalence and the diagnosis of COPD and its Tobacco-related etiology
(RESPECT) study is to gain a better understanding of the prevalence, pathogenesis and symptoms of COPD.
Methods/Design: The RESPECT study is a prospective, population-based cohort study of subjects aged 35–70 years
in two north-west regions of the Russian Federation (Saint Petersburg and Arkhangelsk). The study includes three
components: a cross-sectional study (prevalence), a case-control study and a cohort study (diagnostic). An investigator
who interviewed the patient completed three questionnaires. Spirometry, including a reversibility test, was offered to
all participants. Individuals displaying forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) < 0.7 and/or
FEV1/FVC < the lower limit of normal before and/or after bronchodilation were included in a follow-up study and were
examined by a pulmonologist using a standardized comprehensive examination protocol. A future case-control study
of two matched groups of patients (heavy smokers with COPD versus heavy smokers without COPD) will provide
information on which factors (biomarkers, including pneumoproteins, in serum and induced sputum) are related to
tobacco-induced COPD.
Discussion: In total, 3133 individuals (2122 from St. Petersburg and 1012 from Arkhangelsk) aged 35–70 years agreed
to participate in this study and met the inclusion criteria. In total, 2974 participants met the quality criteria for
spirometry, and 2388 reversibility tests were performed. A cohort of newly defined obstructive pulmonary disease
patients (247 persons) was established for follow-up investigation.
The RESPECT study will provide information regarding the prevalence of COPD in the north-west region of the
Russian Federation. Moreover, the comprehensive RESPECT database will enable us to explore new research
questions, provide novel insight into the risk factors and different phenotypes of COPD, and contribute to an
improved understanding of the reasons why some heavy smokers develop the disease whereas others do not.
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Background
Chronic obstructive pulmonary disease (COPD) remains
a major public health problem in the 21st century. COPD
is one of the leading causes of morbidity and mortality
worldwide and results in an economic and social burden
that is both substantial and increasing [1].
In the Russian Federation (RF), COPD represents more
than 55 % of all pathologies of the respiratory system [2].
At present, approximately 2 million cases of COPD have
been reported in the RF, but the actual number is estimated
to be approximately 11 million [3, 4]. Several attempts to
estimate the prevalence of COPD in different regions of the
RF have been undertaken. These studies revealed significant
differences in the prevalence of COPD based on sex, age,
ecological conditions, socioeconomic status, and smoking
habits, resulting in prevalence rates ranging from 1.8 to
32.0 % [5, 6]. Therefore, there is a consensus that the preva-
lence of COPD in the RF is underestimated and that
additional reliable data are needed.
Smoking is a major risk factor for COPD, and this
behavior is highly prevalent in the RF. A total of 39.1 %
of all Russians (43.9 million) are current smokers
(60.7 % of males and 21.7 % of females) [7]. Higher-
educated Russians (vocational secondary: 41.3 %, higher
education: 38.1 %) are more frequent smokers than less-
educated Russians (primary: 18.0 %). Smoking is also
more prevalent among urban populations (40.2 %) com-
pared with rural populations (35.9 %).
Occupational hazards and both outdoor and indoor pol-
lutants are also important risk factors for COPD [8–11].
Price et al. developed a symptom-based questionnaire
for the identification of patients at increased risk of airflow
limitation (AL) [12, 13]. Their COPD diagnostic question-
naire consists of 8 items and discriminates between sub-
jects with and without AL. These authors concluded that
their questionnaire could be used to identify patients
displaying a high likelihood of exhibiting AL and that
combining this questionnaire with spirometry could po-
tentially improve the efficiency and accuracy of COPD
diagnoses in primary care. However, Kotz et al challenged
these findings and demonstrated that this questionnaire is
likely not useful as a diagnostic tool for the identification
of patients with an increased risk of AL in a high-risk
population consisting of middle-aged current smokers
with a smoking history of ≥ 10 pack-years [14]. A recent
systematic review of the diagnostic value of patient history
and physical examination concluded that the available
evidence is very limited and does not accurately determine
which characteristics of patient history and physical exam-
ination are appropriate to be used by physicians to identify
patients suspected to exhibit COPD who require spirom-
etry [15].
A recently proposed combined COPD assessment tool
[1] not only focuses on the degree of AL but also
considers symptoms, the degree of dyspnea (measured
using the Modified Medical Research Council Dyspnea
Scale (mMRC)) [16, 17] and the number of COPD exacer-
bations. However, it remains commonly accepted that AL,
as measured by spirometry, is a hallmark of COPD [1]
and is essential for the early detection of the disease [18].
Initially, AL was defined as a ratio of the forced expira-
tory volume in 1 s (FEV1) to the forced vital capacity
(FVC) that was below the fifth percentile of a large healthy
reference group (the statistically defined lower limit of
normal (LLN)) [19]. Subsequently, the European Respira-
tory Society/American Thoracic Society (ERS/ATS) COPD
guidelines and the Global Strategy for Diagnosis, Manage-
ment and Prevention of COPD (GOLD) proposed the use
of a fixed ratio of 0.7 (FEV1/FVC < 0.7) [20]. Lung function
tests using 80 % predicted and fixed threshold values to
determine whether a result is abnormal misdiagnosed 20 %
of patients referred for pulmonary function assessment
[19]. This misclassification is avoided by using the LLN,
which is based on the fifth percentile value [20]. The LLN
may be less than an FEV1/FVC of 0.7 after approximately
45 years of age. In 2005, an ATS/ERS pulmonary function
interpretation guideline strongly recommended the use of
the LLN for FEV1/FVC to define AL [20]. Recently, the
GOLD committee acknowledged that “using LLN values
for FEV1/FVC that are based on the normal distribution
and classify the bottom 5 % of the healthy population as
abnormal is one way to minimise the potential misclassifi-
cation” [1, 20].
The Global Lung Function Initiative (GLI, ERS Task
Force) published multi-ethnic reference values for spir-
ometry in the 3- to 95-year age range in the 2012 global
lung function equations [21]. Currently, the spirometry
prediction equations for the 3- to 95-year age range
(including the appropriate age-dependent LLN) are
available and can be applied globally to different ethnic
groups [22].
At present, it remains unclear why some smokers
develop COPD whereas others do not. Furthermore, it is
unclear why COPD occasionally develops in non-smokers.
Certain inflammatory and immune parameters differ
between smoker and non-smoker COPD patients and cor-
relate with AL, especially with the decline in the FEV1
[23]. COPD is characterized by increased levels of inflam-
matory cytokines, such as interleukins (ILs) IL-1β, IL-4,
IL-8, and IL-12 and other proteins, such as chemotactic
cytokine (C-C motif ligand, CCL) CCL5, CCL3, macro-
phage migratory inhibitor factor (MIF), soluble intercellu-
lar adhesion molecule (sICAM), granulocyte chemotactic
activity (GCA) and surfactant protein D (SP-D), in exhaled
breath condensate. Simultaneous significant decreases in
IL-1β, IL-6, IL-8, IL-12, tumor necrosis factor (TNF-α)
and Clara cell protein have been detected in stable COPD
patients compared to active smokers who did not exhibit
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clinical signs of COPD [23]. The type of inflammatory
process in COPD is not well characterized and may vary
among patients. COPD displays elements of bronchitis,
airway hyperreactivity, pulmonary emphysema and inflam-
mation in variable proportions, and it appears unlikely that
all patients with COPD exhibit the same underlying disease
processes [24].
The determinants of persistent systemic inflammation
among patients with COPD include age, body mass index
(BMI), smoking and AL [25]. In addition to smoking,
certain pathogenic mechanisms, such as chronic inflam-
mation, abdominal obesity, and physical inactivity, are
most likely involved in the development of COPD [26].
Presently, major advances in the understanding of the
mechanisms underlying COPD have been made, but
many important questions about the pathogenesis and
diagnosis of COPD remain. Further research is needed
to resolve these questions [27], presenting new challenges
for researchers.
Recently, a series of recommendations for epidemio-
logical studies of COPD were published in a task force
report by the ERS [28]. The authors recommended
using clear diagnostic criteria and standardized
methods to examine COPD and all potential risk fac-
tors for COPD. Studies of COPD in the population at
large should also assess various phenotypes of this
disease.
This report suggests measuring as many different
characteristics of COPD patients as possible to contrib-
ute to an understanding of the disease that is well beyond
spirometry classifications.
The aim of our study is to gain a better understanding
of the prevalence, pathogenesis and symptoms of early
COPD. This study seeks to address the following specific
objectives/research questions: 1) to estimate the preva-
lence of AL and COPD in adults 35-70 years of age in
St. Petersburg and Arkhangelsk based on sex, age, envir-
onmental conditions, socioeconomic status and smoking
status; 2) to compare the prevalence of COPD in the
study population based on the GOLD and LLN criteria;
3) to identify the diagnostic value of various signs, symp-
toms and background characteristics for the diagnosis of
COPD; 4) to determine whether differences in back-
ground characteristics, inflammatory biomarkers and
pneumoproteins are evident between smokers with and
without COPD; and 5) to describe co-morbidity, func-
tionality and global health status in a cohort of newly
diagnosed COPD patients.
Methods
The RESearch on the PrEvalence and the diagnosis of
COPD and its Tobacco-related etiology (RESPECT)
study is a collaboration between Université Catholique
de Louvain (Belgium), the North-West State Medical
University (named after I.I. Mechnikov, St. Petersburg) and
the Northern State Medical University, Arkhangelsk (RF).
Setting
Two northwestern RF cities (St. Petersburg and Arkhangelsk)
were selected for the RESPECT study. The population
sizes of St. Petersburg and Arkhangelsk have been esti-
mated as 4,869,600 citizens (1st January, 2011) [29] and
356,500 citizens (1st January, 2010), respectively [30].
Fifteen primary care centers were invited to participate
in this study. These centers are located in different areas
of these cities (some in highly polluted areas, others in less
polluted areas) and were selected to provide adequate
coverage of the different districts.
Fifteen investigators (10 from St. Petersburg and 5 from
Arkhangelsk) were recruited (predominantly doctors and
two highly educated nurses). All investigators received
study information, including a detailed study protocol and
recent guidelines on COPD, and participated in a three-
week course on spirometry and the clinical diagnosis and
management of obstructive lung diseases.
Design
This study includes three components: a cross-sectional
study (prevalence and diagnostic), a case-control study
and a cohort study (Fig. 1).
Study I (prevalence and diagnosis)
Sample size calculations
The sample size was calculated based on two goals: 1) to
determine a reliable estimate of the prevalence of COPD
and 2) to estimate the diagnostic value of symptoms
with an acceptable confidence interval.
To generate a reliable estimate of the prevalence of
COPD, for which 8 % prevalence in the RF was assumed,
the following formula was used: n ¼ Z2P 1−Pð Þ
d2
, where n is
the sample size, Z is the Z statistic for a level of confi-
dence (95 %), P is the expected prevalence (8 %), and d
is the desired precision (1 %) [31]. Therefore, based on
our prevalence considerations, the sample size for the
RESPECT study was estimated using 2828 subjects.
To estimate the diagnostic value of various signs and
symptoms with an acceptable confidence interval (the
second focus of our cross-sectional study), sample size con-
siderations were based on the following premises: 1) the ex-
pected prevalence of important symptoms (i.e., chronic
cough, dyspnea, wheezing, chronic phlegm) of COPD in
the general population was 10 %; 2) a worst-case scenario
that none of these criteria displayed any diagnostic value
(i.e., the proportion of each symptom would be 0.5 in each
group) given an acceptable confidence interval of 95 %; and
3) based on an 8 % prevalence of COPD. Based on these
premises, a sample size of 864 was established.
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Based on both of these approaches and assuming an
anticipated refusal rate of 20 %, 3500 participants from
St. Petersburg and 1500 from Arkhangelsk were invited
to participate in this study.
In order to estimate the sample size needed for the
case-control study the following formula was used
n ¼ rþ1r
  σ2 ZβþZα=2ð Þ2
differenceð Þ2 ; r stands for the ratio cases/
controls (we choose for an equal number of cases
and controls), Zβ = the desired power (for 80 %
power Zβ = .84) , Zα/2 = the desired level of signifi-
cance (for 0.05 significance level, Zα/2 =1.96), σ
2 =
the variance of the outcome variable (for Log hCRP = 0.25 )
and d = the difference in means that is considered meaning-
ful (for log hCRP we used 0.4 as the minimum meaningful
difference). The number of cases and controls needed was
estimated in this way as 63. Taking into account a potential
drop out of 10 % it was decided to involve 70 heavy
smokers with established airflow limitation and 70 heavy
smokers with normal lung function.
Population
The study population was randomly selected from the
lists of the 15 participating centers (these patient lists
are organized based on territories).
This study focused on the early stages of COPD; there-
fore, participants aged 35–70 years were selected from
each center using a random number generator and were
subsequently invited to participate.
Questionnaires
Several questionnaires were used to collect data using
specifically designed software. All results were subse-
quently uploaded to a central database using the WiPam
application [32].
Background characteristics included variables such as
sex, age and socio-demographic status.
Socioeconomic status was mapped as suggested by W.
C. Cockerham [33]. A total score was calculated as the
sum of marital status (single, divorced, widowed (0) or
married (1)), education (primary school or none (1),
unfinished secondary education (2), secondary education
(3), secondary vocational education (4), unfinished higher
education (5) or higher education (6)), income (insufficient
nutrition (1), minimally sufficient for food/clothing (2), suf-
ficient to purchase TV/refrigerator but not a car or housing
(3) or can purchase expensive goods (car/housing) (4)),
and occupation (agricultural/unskilled worker (1), skilled
worker (2), office clerk without higher education (3), man-
ager/professional (4) or top manager (5)) [33].
Smoking anamnesis
Smoking status was specified as never smoker, former
smoker (quit smoking 6 month ago or longer), or current
N=3133 (A. 1012; StP 2122)
Background variables, Q1 - symptoms, Q2- IPCRG
FEV1/FVC<0.7 (GOLD) or <LLN, 
N=247
FEV1/FVC 0.7 (GOLD) or LLN, 
N=2727
Bronchodilator test
FEV1 200 ml FEV1 200 ml & 12%
Examination by pulmonologist, 
blood, swab
Spirometry 
COPD; COPD + Asthma, n=162
Cases (n=100):
COPD+; GOLD stages II-IV; 
Smoking history>10 pack/years
Controls (n=100): 










Fig. 1 Design of the RESPECT study. A =Arkhangelsk, StP = Saint Petersburg, Q =questionnaire, IPCRG= International Primary Care Respiratory Group, V = visit,
S = Study (S1 – cross-sectional, S2 – case-control, S3 – cohort), GOLD=Global Initiative for Chronic Obstructive Lung Disease, COPD=Chronic Obstructive
Lung Disease. FEV1 – forced expiratory volume in 1 s, FEV1/FVC= forced expiratory volume in 1 s/forced vital capacity ratio, LLN= lower limit of normal
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smoker. Former and current smokers were asked about
the age at which they began to smoke, how many years
they had smoked and how many cigarettes per day they
had smoked (in pack-years). One pack-year of smoking
indicates that an individual smoked one package of cig-
arettes (20 cigarettes) daily for one year.
Passive smoking status was defined as both current
smoking behavior using an environmental tobacco smoke
(ETS) questionnaire [34] and lifetime ETS exposure [35].
The ETS questionnaire includes questions about short-
term tobacco exposure (the past 7 days) in the household
(living with smokers) or at other tobacco-polluted indoor
or outdoor locations (e.g., any home, workplace, bar,
nightclub, sport arena or concert hall). The lifetime ETS
exposure questionnaire accounts for the long-term effects
of tobacco exposure (the smoking status of the mother
during pregnancy, the number of years in total that the
subject lived with smokers, and how many years the sub-
ject was exposed to tobacco at the workplace). Environ-
mental hazards (the number of years that the subject had
lived in a polluted area) were also considered.
Occupational exposure
Occupational hazards (working in a dusty/toxic job) and
indoor exposure to biomass fuels were assessed using
additional questionnaires [36, 37]. The ATS 1978 Adult
Questionnaire (ATS-DLD-78) was used to assess expos-
ure to occupational hazards [36]. The participants were
asked about working for one year or more in any dusty
job, exposure to gas or chemical fumes, and the use of
protective equipment. Limitations in work based on
health problems or retirement were considered.
Exposure to indoor biofuel pollution
The participants were asked about personal gas or wood/
stove use to estimate indoor exposure to biomass fuels
[37]. Gas stove utilization ratings included none, low use
(1–6 times/week) or high use (>7 times/week). Similar rat-
ings were used for wood stove utilization: none, low use
(1–4 times/week) or high use (>5 times/week).
Patient-reported family history and comorbidities
Information regarding family history of obstructive airway
disease (asthma, chronic bronchitis, emphysema, chronic
cough, and allergic rhinitis), personal history, including
tuberculosis anamnesis, and co-morbidities (diabetes
mellitus, myocardial infarction, arterial hypertension,
arthritis, and allergic diseases) was collected in a system-
atic manner (yes or no). Additionally, the investigators
recorded details regarding the use of current medications.
Respiratory symptoms
The participants were questioned about three primary
symptoms (chronic cough, chronic sputum and a chronic
dyspnea) [38]. The presence of chronic cough and chronic
sputum production (defined as lasting more than 3 months)
and chronic dyspnea were categorized as a chronic respira-
tory symptom.
Differential diagnosis between asthma and COPD
The International Primary Care Respiratory Group ques-
tionnaire was used to differentiate between asthma and
COPD before spirometry [39, 40]. This questionnaire in-
cluded questions regarding age, smoking history, respiratory
symptoms, history of hospitalizations and treatment. The
scoring system of this questionnaire utilizes a sum of the
total number of points based on the patient’s responses: a
score of 18 or less indicates a diagnosis of asthma, whereas
a score of 19 or more suggests a diagnosis of COPD.
Spirometry
All participating investigators were invited to participate
in a distance-learning course on spirometry, SpiroCourse
[41, 42]. SpiroCourse was created and implemented by
the RESPECT research team and was designed as a
three-week E-learning course based on active learning
principles. This course includes three tutorial modules
(with assignments and quizzes), a library containing the
most recently updated relevant guidelines, clinical cases
and a discussion forum. The first module involves the
fundamentals and procedures of spirometry. The second
module focuses on acceptability and reproducibility
quality criteria and reversibility testing. The third mod-
ule focuses on comprehensive analyses, interpretation of
the flow-volume curve and numerical data and quality con-
trol procedures. Practical training sessions (face-to-face),
during which each participating investigator was required
to demonstrate the skills required for this study, were orga-
nized in St. Petersburg and Arkhangelsk. All investigators
completed the course successfully and agreed to receive
continuous quality feedback on the exams.
Equipment
All centers were equipped with a portable turbine micro-
spirometer (MIR Spirobank, Rome, Italy) and a personal
computer equipped with the WiPam program to facilitate
the upload of data to a central database. The Spirobank
device is a hand-held instrument for lung function tests
that can be connected to a computer. The accuracy of
spirometry performed by the trained investigators using
this equipment was previously examined in detail and is
well documented [18]. The Spirobank spirometer per-
formed very well in a laboratory environment compared
with the Jaeger MasterScope, displaying a 2–5 % under-
estimation of the FEV1 and the FEV1/FVC. Moreover, we
demonstrated that only 2 % of the observed variation in
the measurement results could be explained by the type of
device used under real-life conditions and that other
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sources of variation, such as the timing of the test, are
more important than the small measurement error caused
by the device itself.
Winspiro Pro software (MIR) was used to compare
the measured values with those in reference tables and
to automatically calculate the reproducibility of the per-
formed spirometry in accordance with the ERS guide-
lines. The predictive values were calculated using Global
Lung Initiative (GLI2012) Data Conversion software [22].
Two cut-offs values were used to define AL: FEV1/FVC< 0.7
(fixed cut-off) and FEV1/FVC < LLN (5
th percentile of z-
scores of the GLI 2012 reference values).
Procedure
The pre- and post-bronchodilator spirometry test mea-
surements were recorded. Reversibility testing using
400 μg of salbutamol or 160 μg of ipratropium bromide
(for patients older than 60 years or with comorbid car-
diovascular disease) was offered to all participants. The
second spirometry test was performed 15 (salbutamol)
or 45 min (ipratropium bromide) after the first spirometry
test. The Spirobank G turbine-microspirometer does not
require calibration and has an internal temperature sensor
for automatic BTPS conversion [43]. Routine multiple-
speed volume calibration checks are not mandatory with
this equipment. Nevertheless an extra calibration proced-
ure was organized twice during the research using a 3 liter
calibration syringe and no significant deviations were
detected.
Quality assessment
The ERS/ATS quality criteria were used to assess the
acceptability and repeatability of the results [44]. The
ATS/ERS criteria of spirometry quality include the fol-
lowing parameters: FVC minimal duration, 6 s; the FVC
“end of test” criteria (or the volume-time curve shows
an obvious plateau or the volume time curve shows an
obvious plateau or the forced exhalation is of reasonable
duration); maximum number of FVC maneuvers, 8;
absence of artifacts; and maneuver repeatability. The
repeatability criteria are used to determine when more
than three acceptable FVC maneuvers are required;
these criteria are not suitable for the exclusion of
results from reports or for the exclusion of subjects
from a study [44]. Acceptable repeatability is achieved
when the difference between the largest and the second-
largest FVC is ≤ 0.150 L and the difference between
the largest and the second-largest FEV1 is ≤ 0.150 L.
For individuals displaying an FVC of ≤ 1.0 L, both of
these values are recorded as 0.100 L [44].
After assessment, all spirometry results were classified
according to 4 categories: ATS1, all ATS/ERS criteria,
including reproducibility, were satisfied; ATS2, all criteria
except for duration of expiration > 6 s were satisfied;
ATS3, the test was “usable” for the interpretation of the
PEF and FEV1, and the spirograms displayed good starts
and no cough noted during the 1st second of the maneu-
ver; and ATS4, none of the ATS/ERS criteria were satis-
fied, and the spirograms were not usable. Spirograms
scored as ATS1 or ATS2 were considered to be of accept-
able quality.
Sensitivity analysis
Sensitivity Analysis is defined as “ a method to determine
the robustness of an assessment by examining the extent
to which results are affected by changes in methods,
models, values of unmeasured variables or assumptions”
with the aim of identifying “results that are most dependent
on questionable or unsupported assumptions” [45]. It has
also been defined as a series of analyses of a data set to
assess whether altering any of the assumptions made leads
to different final interpretation and conclusions” [46].
With increasing rates of non-participation in surveys
and studies, the inherent uncertainty and potential for
bias that accompanies non-response increases. Different
adjustment methods have been proposed. The choice of
an adjustment method depends on the assumptions that
are considered plausible regarding the nature of the
non-participation and the type of additional sources of
data that are available.
In our study no information about the invited persons
that refused to participate to the study is available. We
assume that the non-participants are missing at random
i.e. that the probability of being missing is not dependent
on unobserved data, given the observed data.
However since the issue of a possible participation bias
is so essential we decided to perform a sensitivity ana-
lysis to assess the robustness of our prevalence figures.
The sensitivity analysis will be based on three different
approaches: (1) a post-stratification strategy, (2) a reweight-
ing procedure and (3) an extreme case scenario i.e. simula-
tion of the impact on the overall prevalence starting from
two hypotheses: 1. All of the non-responders are smokers
2. None of the non-responders are smokers. We will com-
pare the results of these simulations with the original preva-
lence figures [47].
Study II (case-control study)
Study population and sample size
One hundred patients with COPD and a smoking his-
tory of more than 10 pack-years (cases) and one hun-
dred patients with the same smoking history without
COPD (controls) will be invited in the second study in
order to reach the needed sample size of 2 × 70
patients.
The inclusion criteria for the cases and the controls
include the following: 1) a smoking history of more than
10 pack-years and 2) age between 35 and 70 years.
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The cases and the controls will be matched based on
the following criteria: age group, sex, smoking history,
level of pollution in living area, body mass index, comor-
bidity (cardio-vascular diseases index, systemic disease,
and tuberculosis in anamnesis), and use of medications
that may influence the inflammatory status.
The cases will include 100 participants that meet the
following criteria: 1) smokers aged 35–70 years with a
smoking history of >10 pack-years; 2) completely irrevers-
ible AL based on the following criteria: FEV1/FVC < 0.7
according to the GOLD criteria (fixed threshold) or FEV1/
FVC < LLN; 3) COPD of stage II-IV according to the
GOLD criteria (post-bronchodilation FEV1 < 80 % of the
predicted value) or the LLN criteria (FEV1 below the
LLN); and 4) a confirmed diagnosis of COPD by a pulmo-
nologist after a comprehensive clinical examination.
The controls will include 100 participants based on
the following criteria: 1) smokers aged 35–70 years
with a smoking history of >10 pack-years and with-
out COPD according to the GOLD or LLN criteria,
2) without asthma (absence of symptoms), 3) no his-
tory of allergies, and 4) free from the use of
bronchodilators.
Assessment of cases and controls
All of the tests listed below: mMRC, the COPD
Assessment Test (CAT) [16], the Hospital Anxiety
and Depression Scale (HADS) [48], the WHO Fracture
Risk Assessment Tool (FRAX) [49], and a 3-level ver-
sion of the EuroQol 5-dimensional descriptive system
(the EQ-5D-3 L) [50–52] will be offered to all cases and
controls.
Symptoms
The mMRC scale uses a simple grading system to assess
a patient's level of dyspnea (0, patient only becomes
breathless with strenuous exercise; 1, patient becomes
short of breath when hurrying on level ground or walk-
ing up a slight hill; 2, on level ground, patient walks
slower than people of the same age due to breathlessness
or must stop for breath when walking at his/her own
pace; 3, patient stops for breath after walking approxi-
mately 100 m or after a few minutes on level ground;
or 4, patient is too breathless to leave the house or he/
she is breathless when dressing). The CAT test is a vali-
dated, short (8-item) and simple patient-completed
questionnaire that displays adequate discriminatory
properties that was developed for use in routine clinical
practice to measure the health status of patients with
COPD [53]. The CAT test is scored in a range of 0 to
40. A CAT test score greater than or equal to 10 indi-
cates a high level of symptoms, and an mMRC scale
score greater than or equal to 2 indicates pronounced
dyspnea [1].
Psychosocial measurements
The HADS is used to determine the levels of anxiety and
depression experienced by the patients [48]. The score for
each subscale (anxiety and depression) ranges from 0 to
21, and these scores are categorized as follows: normal
(0-7), mild (8-10), moderate (11-14), and severe (15-21).
Scores for the entire scale (emotional distress) range from
0 to 42; higher scores indicate greater distress.
Fracture risk
The FRAX was used to evaluate the fracture risk of patients
[49]. The FRAX algorithm computes the 10-year prob-
ability of a fracture. FRAX considers the following risk
factors: age, sex, previous fracture, parent fractured hip,
current smoking, glucocorticoid use, rheumatoid arth-
ritis, secondary osteoporosis, and 3 or more alcohol
units consumed per day. A unit of alcohol is equivalent
to a standard glass of beer (285 ml), a single serving of
a spirit (30 ml), a medium-sized glass of wine (120 ml),
or 1 serving of an aperitif (60 ml).
Quality of life
A 3-level version of the EuroQol 5-dimensional descrip-
tive system (the EQ-5D-3 L) was used as a standardized
measure of health status [50–52]. The EQ-5D-3 L con-
sists of 2 instruments: the EQ-5D descriptive system and
the EQ visual analog scale (EQ VAS). The EQ-5D-3 L
descriptive system assesses the following 5 dimensions:
mobility, self-care, typical activities, pain/discomfort and
anxiety/depression. Each item is scored according to 3
levels: no problems, some problems and extreme prob-
lems. The respondent is asked to indicate his/her health
state by selecting the box that corresponds to the most
appropriate statement in each of the 5 dimensions. The
EQ VAS records the respondent’s self-rated health on a
vertical, visual analog scale in which the endpoints are
labeled “best imaginable health state” and “worst imagin-
able health state”. This information can be used as a
quantitative measure of health outcome as judged by the
individual respondents [52].
Laboratory testing
Blood samples were collected from all patients exhibit-
ing AL after fasting (between 7:00 AM and 10:30 AM)
and were immediately stored in a refrigerated container
until arrival at the central laboratory (<3 h after blood
collection). Plasma (EDTA, heparin) or serum samples
were obtained after centrifugation. A hemogram, includ-
ing counts of red (RBCs) and white blood cells (WBCs)
and leukocytes, was immediately performed at one of 2
laboratories (in St. Petersburg and Arkhangelsk) upon
arrival. Aliquots of serum were stored in a freezer at -80°
for subsequent analysis at the central lab in St. Petersburg.
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Mucosal swabs were collected and frozen for future gene
analysis.
The following laboratory tests will be performed on all
cases and controls: blood counts (WBCs and RBCs), the
levels of cholesterol, triglyceride, creatinine, glucose,
AST, ALT, high-sensitivity C-reactive protein (hs-CRP),
IL-4, IL-6, IL-8, IL-10, TNFα, Clara cell protein, SP-D,
vitamin D protein, MMP-9, TIMP-1, and α1-antitrypsin,
and genetics (DNA from buccal swab for the identifica-
tion of polymorphic variants of the RIN3, MMP12, and
TGFB2 genes). In 30 cases and 30 controls, induced spu-
tum will be examined for the concentrations of neutro-
phils, lymphocytes, eosinophils, CC16, IL-8, TNFα and
immunoglobulin (IgG).
Study III (an ongoing prospective cohort study with two
years of follow-up)
Study population
All newly identified individuals with an FEV1/FVC of less
than 0.7 or less than the LLN before and/or after the re-
versibility test were included in the cohort study. All diag-
nosed cases exhibiting irreversible AL (FEV1 < 200 ml and
12 % after bronchodilation) were subsequently identified.
After the initial assessment of each participant in this
cohort (baseline (T0) and examination by pulmonologist
(T1)), two follow-up visits are scheduled: one year (T2)
and two years (T3) after the initial visit.
Assessment of patients with AL
All newly detected individuals displaying an FEV1/FVC
less than 0.7 or less than the LLN before and/or after
the reversibility test are examined using a comprehen-
sive standardized protocol by one of the two principal
investigator both experienced pulmonologists.
Symptoms and additional variables
Evaluation of the symptoms was based on the mMRC
scale [17] and the CAT [16].
The following parameters were assessed at inclusion:
risk factors (smoking, occupational hazards and family
history of obstructive lung disease); the history of
hospitalization and treatment; obstructive disease ex-
acerbation frequency; current known diseases; family
anamnesis; a standardized physical examination that in-
cludes lung and heart auscultation; measurements of
height, weight, BMI, waist circumference, pulse, respira-
tory rate and blood pressure; and skin and edema
assessments.
Co-morbidity
The presence/absence of the following diseases was
systematically recorded: asthma, allergic disease, chronic
bronchitis or emphysema, bronchiectasis, sinusitis, arter-
ial hypertension, ischemic heart disease, heart failure,
diabetes, cerebrovascular or peripheral artery disease,
depression, cancer, osteoporosis, arthritis, peptic ulcer
disease, hepatitis, cirrhosis, kidney disease, and previous
myocardial infarction, pulmonary embolism and stroke.
Additional assessments
The same measurements were performed to all: the
HADS to determine the levels of anxiety and depression
[48], the FRAX to evaluate the fracture risk [50] and the
EQ-5D-3 L [51–53] to measure the quality of life.
Spirometry
For all patients exhibiting AL, a spirometry test was per-
formed during the comprehensive assessment (T1) within
a 6-month interval after inclusion in the cross-sectional
study (T0) and will be subsequently performed 12 and
24 months after the first examination (T2, T3).
Laboratory testing
The following laboratory tests will be performed: WBC
count, RBC count, and the levels of cholesterol, triglyceride,
glucose, AST, ALT, creatinine, fibrinogen, TNFα, IL-4, IL-6,
IL-8, IL-10, hs-CRP, Clara cell protein and SP-D. During
the first (initial) visit the following lab parameters will be in-
vestigated: Nt-proBNP, vitamin D protein, MMP-9, TIMP-1
and α1-antitrypsin.
Future investigations
All participants will be invited for follow-up investigations.
Multispiral computer tomography (CT) and pulmon-
ary functional tests will be offered to a subset of patients
(priority given to patients with stage I-II COPD). Newly
identified obstructive lung disease patients will be offered
body plethysmography to determine total lung capacity
(TLC).
After the baseline assessment (T0) and the follow-up
examination, a consensus clinical diagnosis will be attained,
and both assessments (T1, T2) will be used as an initial and
final “reference standard” in the diagnostic study.
Statistical analysis
All data are stored in a central database. SPSS version
20.0 (SPSS Inc., Chicago, IL, USA) will be used for data
analysis. The analyses will include cross-sectional and
prospective approaches. Prospective analyses will be per-
formed on the entire cohort. The outcome measures will
be registered for every patient who underwent at least
one module of the assessment. The variety of dimen-
sions included in the RESPECT will enable us to correct
for a wide range of factors in the analyses and multivari-
ate models.
Using bivariate and multivariate analyses correlates for
COPD and potential confounders for COPD prevalence
(by comparing the COPD prevalence between the GOLD
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and LLN criteria) will be investigated. Furthermore, vari-
ous clinical phenotypes of COPD (based on clustering
analysis) will be considered.
Future analysis and publications using this cohort will
be performed according to the STROBE criteria [54].
Ethics
All participants provided informed consent. The local
medical ethics review boards (North-West State Medical
University named after I.I. Mechnikov, St. Petersburg,
protocol N 11 from 07.12.2011, and Northern State
Medical University, Arkhangelsk, RF, protocol N 01/1-12
from 11.01.2012) approved these studies.
Results
Participants aged 35-70 years from the patient list from
each center were selected using a random number gen-
erator; initially, 4419 individuals were invited to partici-
pate in the study. In total, 3133 individuals agreed to
participate and met the inclusion criteria. In addition,
2974 participants demonstrated satisfactory quality on
spirometry (after comprehensive quality assessment for
reproducibility and acceptability) (Fig. 2). Basic spirom-
etry analysis revealed 247 participants with obstructions
before bronchodilation (FEV1/FVC < 0.7). Good-quality
bronchodilator tests were obtained from 2388 partici-
pants. Of these participants, 162 were patients with AL
(FEV1/FVC < 0.7), including 130 patients with irrevers-
ible lung obstruction (FEV1 < 200 ml or 12 % after
bronchodilation).
The age and sex distribution of the total RESPECT
population is presented in Fig. 3. The background char-
acteristics of the RESPECT population based on sex are
presented in Table 1. The mean age of the sample popula-
tion was 54 years (SD 9.25), and 31.8 % of the RESPECT
population was male. No significant differences were
detected in the age groups or in the overall socio-economic
status between men and women. In total, 73.3 % of men
and 35.9 % of women were current or ex-smokers
(P < 0.05). Women smoked for a shorter duration
than men (21.1 years, SD 11.9 versus 28.4 years, SD
12.9, P < 0.05). Men more frequently reported exposure to
occupational hazards than women (38.7 and 24.9 %,
respectively, worked at a dusty job; 37.4 and 21.9 %, re-
spectively, exposed to gas or chemical fumes, P < 0.05).
Asthma was indicated as a current known disease
(according to the patient) more often by women, whereas
men more frequently reported emphysema (P < 0.05).
Cough and sputum > three months was more frequently
reported by men than by women (22.7 and 18.0 %, respect-
ively, P < 0.05), whereas dyspnea was indicated more often
by women (9.2 %, P < 0.05).
The RESPECT population differed from the total
population of the north-west region of the RF [55] with
respect to age and sex (Fig. 4). The RESPECT population
includes more women than the average population in
the north-west region (68.2 % versus 55.3 %, respect-
ively, P < 0.05), as well as more participants aged 55–70
years (53.7 % versus 35.3 %, respectively, P < 0.05). The
RESPECT population includes less current and ex-smokers
than the average Russian population [7] (47.8 % versus
53.9 %, respectively, P < 0.05). The smoking status of the
two populations (total and within the sex groups) is pre-
sented in Fig. 5.
Discussion
The RESPECT study was designed to attain a better under-
standing of the epidemiology of AL among the population
of the north-west region of Russia based on the GOLD and
LLN criteria and to examine the pathophysiological
changes in the lungs in smokers without AL during the
early stages of COPD.
COPD prevalence
A recent systematic review of the global burden of COPD
provides a quantitative summary of the global literature
on COPD prevalence, including high-quality estimates of
COPD in important subgroups defined according to age,
smoking status and sex [56]. The pooled estimate of the
COPD prevalence in 37 selected studies was 7.6 %.
However, significant heterogeneity was identified in the
COPD prevalence, and this heterogeneity was incom-
pletely explained by subgroup analyses. One source of
heterogeneity is the diversity of the diagnostic defini-
tions that are used. In addition, a wide range of ages
was examined in the different studies. This review
highlights the lack of good-quality prevalence data from
outside Europe and North America.
According to the Burden of Obstructive Lung Disease
(BOLD) study, the prevalence of stage II or higher COPD
was 10.1 % overall, including 11.8 % for men and 8.5 % for
women [57]; however, no data from Russia were available.
Only one Russian study reporting population-based COPD
prevalence estimates was published during the period from
1990 to 2004 [58]. A few Russian regional studies presented
a COPD prevalence estimate for specific populations (e.g.,
in the Samara region for individuals 30 years and older, the
estimated COPD prevalence rate was 14.5 % overall, includ-
ing 18.7 % for men and 11.2 % for women) [5, 6]. However,
to our knowledge, no national COPD prevalence data based
on population research for the RF are available. Recently
the results of a study in the RF using the Global Alliance
against Chronic Respiratory Diseases (GARD) protocol was
reported [59]. However in this study only patients present-
ing symptoms were included i.e. patients with a higher pre-
test likelihood of presenting the disease. Therefore the
results have to be interpreted with caution.
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COPD diagnosis
Currently, the debate regarding the criteria to be used
for the diagnosis of COPD, including clinical symptoms,
spirometry testing and pathobiology, is ongoing [12, 14,
60–66]. Clinical diagnoses or, more specifically, patient-
reported diagnoses clearly appear to underestimate the
COPD prevalence. Spirometry provides better estimates,
but this technique has some limitations [56]. In the
RESPECT study all newly detected individuals displaying
an FEV1/FVC less than 0.7 or less than the LLN before
and/or after the reversibility test were examined using a
comprehensive standardized protocol by one of the two
principal investigators both experienced pulmonologists.
Participants without obstruction presenting borderline
values were also included in the cohort and assessed in
the same way.
One primary concern regarding diagnosis involves the
value of clinical symptoms and questionnaires. Evidence
indicates that a patient’s history and physical examin-
ation are inadequate for diagnosing mild and moderate
obstructive lung impairments [61]. Less emphasis should
be placed on the presence of isolated symptoms or signs
in the diagnosis of COPD [62]. Straus et al reported that
although numerous elements of the clinical examination
were associated with the diagnosis of COPD, only 3 were
significant after multivariate analysis (a self-reported
history of COPD (adjusted LR 4.4), wheezing (adjusted
likelihood ratio (LR) 2.9), and forced expiratory time
greater than 9 s (adjusted LR 4.6)) [62]. Doubt remains
regarding the diagnostic value of clinical signs and
symptoms [63], as well as the exact disease prevalence
[64]. The questionnaires used (including the clinical
diagnostic questionnaire (CDQ) and the COPD diag-
nostic questionnaire) have not demonstrated sufficient
or accurate discrimination between patients with and
without COPD for use as a diagnostic tool to identify
RESPECT Flow Diagram 
Invited to participate in the study (n= 4419) 
Refused to participate  
or did not meet inclusion criteria (n= 1286)
Irreversible obstruction (FEV1
< 200 ml or 12%),   n= 130 
Obstructive:                    
FEV1/FVC < 0,7 (n = 162) 
Obstructive:                   
FEV1/FVC < 0,7 (n = 247) 
Non-obstructive: FEV1
Non-obstructive:                
FEV1
/FVC  0,7 (n = 2226) 
/FVC  0,7 (n = 2727) 
Reversible obstruction (FEV1 > 
















































Participants with high quality spirometry tests 
(n=2974)
Refused spirometry (n=14) 
Poor quality spirometry tests (n= 496) 
Positive bronchodilator response 
(FEV1 > 200 ml and 12%, n= 91 
Participants with high quality spirometry with    
bronchodilator test (n = 2388) 
Refused bronchodilator test (n = 540) 
Poor quality post bronchodilator spirometry tests (n = 46)  
Fig. 2 RESPECT Flow Diagram
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patients at increased risk of COPD [14, 65]. Other
studies indicated that a simple self-administered patient
questionnaire could be used to identify patients exhibit-
ing a high likelihood of COPD, for whom spirometry
testing is particularly important [12, 66].
Another diagnostic concern involves the appropriate
threshold value to define AL [21, 67–74].
In 2012, the GLI all-ages reference equations were
made available for different ethnic groups and populations
aged 3-95 years, including appropriate age-dependent
LLN values [21]. The current GLI 2012 equations are sup-
ported by the major international respiratory societies and
may improve the interpretation of spirometry results and
standardize interpretation across centers and countries.
GLI recommends using the LLN for this purpose.
In their current guidelines for the diagnosis and man-
agement of COPD, both GOLD and ATS/ERS recom-
mend the use of the fixed cut-off (0.70) for FEV1/FVC to
define AL [1, 67]. In their guidelines for the interpret-
ation of lung functional tests, ATS/ERS supports using
the LLN at the 5th percentile of the frequency distribu-
tion of a reference “healthy” population as the cut-off
value [68]. The fixed cut-off approach leads to over-
diagnosis of COPD in older adults given that it does not
account for the “normal” age-related decline in respira-
tory parameters, whereas the LLN cut-off approach is
dependent on age-specific reference values derived from
spirometry data of “healthy” never-smokers of an equivalent
age and gender. Due to the increased variability of the
distribution of normal values of spirometry parameters in
older adults, the Lambda Mu Sigma [69] approach of calcu-
lating the LLN, which uses the 5th percentile of the distri-
bution of z-scores (similar to growth charts and the bone
mineral density), is considered to be more appropriate than
the fixed cut-off approach [70–72].
However, Rennard et al [61] stated that the discussion
of the fixed versus LLN cut-offs is highly unlikely to
advance disease understanding and thereby help pa-
tients. They stress distinguishing between two epi-
demiological concepts: AL and COPD. The impact of
the fixed cut-off on the diagnosis of COPD in a clinical
setting is unlikely to be significant when other import-
ant aspects, such as age, exposure to risk factors, symp-
toms, and the severity of AL, are considered [60]. The
authors also concluded that the LLN has limitations, in-
cluding the reference population and its characteristics
(for LLN, this reference population was a large population
of healthy never-smokers without symptoms but not con-
sidering significant determinants of lung function, such as
socioeconomic status). Moreover, whether the “normal”
FEV1 and FVC decline >with age represents health or
unrecognized disease is unknown [60].
Spirometry is the current reference standard for the
detection of AL and the diagnosis of COPD in its preclinical
stage; however, the results must be carefully correlated to
clinical data for optimal application [73]. Quanjer [74]
Fig. 3 Age and sex distribution of the RESPECT population
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emphasized that careful phenotyping using clinical, physio-
logic, and radiologic data might be more relevant to diagno-
sis, prognosis, or both [75, 76] than the fixed FEV1/FVC
ratio.
Why do some smokers develop COPD whereas others do
not, and vice-versa for non-smokers?
Although cigarette smoke is widely acknowledged as
the single most important risk factor for COPD, it is
currently recognized that never-smokers may account
for between one-fourth and one-third of all COPD
cases [76]. The BOLD study reports three primary
findings concerning this issue: 1) never-smokers are a
substantial proportion (28 % of irreversible airway ob-
struction cases occur in never-smokers aged 40 to
98 years) of individuals with COPD, and they are typic-
ally not diagnosed with this disease; 2) more than two-
thirds of never-smokers with moderate to severe airway
obstruction are women; and 3) predictors of COPD in
never-smokers include age, education, exposure to oc-
cupational hazards, childhood respiratory diseases, and
BMI alterations.
In the ECLIPSE [25] study, Agustí et al revealed a distinct
systemic inflammatory network pattern (inflammome) in
Table 1 Background characteristics of the RESPECT population according to the sex
Characteristics Total, n = 3133 Male, n = 996 Female, n = 2137
(31.8 %) (68.2 %)
Demographic
Age, mean ± SD 54.0 ± 9.25 53.8 ± 9.52 54.2 ± 9.13
35-44 620 (19.8) 210 (21.1) 410 (19.2)
45-54 830 (26.5) 259 (26.0) 571 (26.7)
55-64 1278 (40.8) 387 (38.9) 891 (41.7)
65-70 405 (12.9) 140 (14.1) 265 (12.4)
Smoking status
Total 3114 991 2123
Never smoker 1625 (52.2) 264 (26.6) 1361 (64.1)a
Current smoker 917 (29.4) 456 (46) 461 (21.7)a
Ex-smoker 572 (18.4) 271 (27.3) 301 (14.2)a
Socioeconomic status
Total 3114 991 2123
Total scoreb, mean ± SD 10.71 ± 2.52 10.81 ± 2.58 10.68 ± 2.49
Occupational hazard 2912 934 1978
Working at dusty job > 1 year 854 (29.3) 361 (38.7) 493 (24.9)a
Exposed to gas or chemical fumes 782 (26.9) 349 (37.4) 433 (21.9)a
Indoor exposure to biomass fuels
Gas stove use 3114 991 2123
None 1023 (32.9) 329 (33.2) 694 (32.7)
Lower use (1–6 times/week) 171 (5.5) 103 (10.4) 68 (3.2)a
Higher use (>7 times/week) 1920 (67.1) 559 (56.4) 1361 (64.1)a
Wood/coal stove use 3113 991 2123
None 2325 (74.7) 705 (71.1) 1620 (76.3)
Lower use (1–6 times/week) 535 (17.2) 204 (20.6) 331 (15.6)a
Higher use (>7 times/week) 253 (8.1) 82 (8.3) 171 (8.1)
Current respiratory diseases (means by patient) 3059 967 2092
COPD 43 (1.4) 21 (2.2) 22 (1.1)
Asthma 179 (5.9) 23 (2.4) 156 (7.5)a
Emphysema 11 (0.4) 8 (0.8) 3 (0.1)a
Chronic bronchitis 322 (10.5) 91 (9.4) 231 (11.0)
aSignificant differences (P < .05) within the sex group (p-value for Pearson Chi-square test)
bSEC (socioeconomic status) total score compute as a sum of marital status, education, income and occupation
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patients with COPD that differs from that of smokers dis-
playing normal lung function and that of non-smokers.
However, systemic inflammation is not consistently de-
tected in all COPD patients given that 30 % do not abnor-
mally express any inflammatory biomarkers. The ECLIPSE
study also revealed a subgroup of COPD patients displaying
persistently elevated inflammatory biomarker expression
who exhibit relatively similar lung function impairment and
significantly increased all-cause mortality and exacerbation
frequency. These inflamed patients may represent a novel
distinct phenotype of COPD.
Increased levels of various biomarkers (WBCs, IL-8
and TNFα) were identified in smokers exhibiting normal
spirometry results compared with nonsmokers, whereas
similar levels of other biomarkers (CRP, IL-6 and fibrino-
gen) were detected between both groups [25].
Cigarette smoke activates innate immune cells, such as
epithelial cells and macrophages, by triggering pattern
recognition receptors either directly or indirectly via the
release of damage-associated effector molecules from
stressed or dying cells [77]. Activated dendritic cells
induce adaptive immune responses encompassing CD4+ T
helper (Th1 and Th17) cell, CD8+ cytotoxicity, and B-
cell responses, which lead to the development of
lymphoid follicles at sites of chronic inflammation.
Viral and bacterial infections not only cause acute exac-
erbations of COPD but also amplify and perpetuate
chronic inflammation in stable COPD via pathogen-
associated molecular pathways. The role of autoimmunity
(autoantibodies), remodeling, extracellular matrix-derived
fragments, impaired innate lung defenses, oxidative stress,
hypoxia, and dysregulation of microRNAs in the persist-
ence of pulmonary inflammation despite smoking
cessation was discussed by Brusselle et al [77].
One goal of the RESPECT study is to gain a better
understanding of the role of inflammatory biomarkers,
Fig. 4 Age distribution in the RESPECT and in the general population. Data for the general population extracted and calculated from the Russian
Population Census (for the North-West region of Russian Federation): http://www.gks.ru/free_doc/new_site/perepis2010/croc/perepis_itogi1612.htm.
*Significant difference (P < .05) between the two populations within the age group (p-value for Pearson Chi-square test).
Fig. 5 Smoking status for the RESPECT and the general population. Data for the smoking status for the Russian population extracted from Global
Adult Tobacco Survey (GATS): Russian Federation 2009. Country report: http://www.who.int/tobacco/surveillance/en_tfi_gats_russian_countryreport.pdf.
*Significant difference (P< .05) between the two populations within the sex group (p-value for Pearson Chi-square test)
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pneumoproteins and background characteristics in AL.
Furthermore, we hope to correlate these factors to phe-
notypes of early and advanced COPD and to determine
the various aspects of the complex relationship between
tobacco exposure and the development of COPD.
Conclusion
This population-based study will enable us to address
the following new research objectives:
1) To estimate the prevalence of COPD in adults 35–70
years of age in St. Petersburg and Arkhangelsk based
on sex, age, environmental conditions, socioeconomic
status and smoking status using the GOLD and LLN
spirometry criteria;
2) To determine the value of various respiratory signs
and symptoms as diagnostic criteria for COPD;
3) To establish a cohort of newly defined COPD
patients to identify the different phenotypes of
COPD and their association with background
characteristics and the levels of inflammatory
biomarkers and pneumoproteins; and
4) To study the natural history and determinants of
progression of COPD and to describe co-morbidity,
functionality and global health status using a cohort
of newly diagnosed COPD patients.
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